of monoamine oxidase (MAO) by iproniazid appeared. The increase in publication rate that one should expect from this important finding did not appear at once. In fact, it came only after 1957, when the first clinical reports on the use of iproniazid in mental patients were published. However, the gradual increase in work on MAO merely parallels the increase in publications in the field of chemistry as a whole, as depicted by the upper line on the graph, at least until 1960. Then there is an explosive increase in publications on all aspects of MAO. The other curve near the bottom of the graph offers a second control on the MAO line. It represents the number of entries for diamine oxidase (or histaminase) in Chemical Abtracts. It is clear that for many years this number exceeded that for MAO, presumably because of the more distinct relationship of histamine pharmacology to human disease. Perhaps when someone finds a useful anti-allergic One of the main streams of basic research in psychiatry today is the pharmacological approach. This does not refer to classical pharmacology, but to the invasion of the field of drug action by biochemical methods and by biochemical thinking. The old 'active patches' on the cell surface have become receptor sites; the receptors have become specific proteins or even regions of the protein molecule; and the regions are being analyzed in terms of the concatenated amino acids. This work has been very productive; it has increased our knowledge of the biochemical actions of reserpine, the phenothiazines, the amphetamines, and the monoamine oxidase inhibitors. We still do not know how the hallucinogenic agents act, nor for that matter do we know what happens in the brain of a depressed patient during the weeks that he receives one or another drug and begins to respond favourably. The case of monoamine oxidase, an intensively studied enzyme for the purposes of psychiatry, illustrates some of the abiding deficiencies. This enzyme was discovered in 1928 and for many years only the most modest attention was paid to it. In Figure 1 is plotted the number of entries under the rubric 'amine oxidase' in Chemical Abstracts, a publication of the American Chemical Society, from 1945 to the present time. As is evident, little work was being carried on around the world until after 1951, when the number of entries began to increase. This may be correlated with the appearance of new chemical and physical methods for measuring the minute amounts of amines that occur in body fluids. drug that inhibits diamine oxidase or, conversely, an inhibitor of this enzyme that can be used for the treatment of allergic conditions, the diamine oxidase line will shoot sharply upwards also.
The last point to mention in Figure 1 is the apparent levelling-off of the MAO curve in 1963. This is unfortunate, because there are still many problems to be solved in the biochemical pharmacology of MAO and its substrates. We have had much applied research on MAO among all those hundreds of publications, but the best preparations of the enzyme are still impure, no one has isolated a co-factor for it; indeed, no one has presented clear evidence for a co-factor (yet we think the enzyme probably has one!); and we do not know if it is a single enzyme or many. The point is that in exploring the subject, empirical fact-finding is very useful, but we must also seek after the basic.
The Problem of the Chemical Nature of Monoamine Oxidase Several enzymes which act on amines are now known. TIley are listed in Table  1 . Various co-factors have been described for one or another of these enzymes: flavinadenine dinucleotide, pyridoxal phosphate, copper, perhaps zinc.
But, as already mentioned, we are uncertain about MAO. We have explored the known relationship of riboflavin nutrition to MAO activity (12, 25, 29) and have found, for example, that the riboflavindeficient rat is more susceptible to the actions of MAO inhibitors than control animals are (30) . In studies carried out in vitro, we have obtained some evidence that MAO of the liver mitochondria may consist of at least two entities, as judged by pH optima and sensitivity to heat denaturation (31) . This evidence is different from, but backs up, that of Gorkin (11, 24) who also speaks of the multiple nature of MAO. The most important problem in the biochemistry of MAO is that of purification; this is a matter of extricating the enzyme from the mass of mitochondrial protein in which it is embedded, so that its physical and chemical properties can be correctly determined. Mr. M. Youdim in this laboratory is making progress in that direction.
Greater knowledge of the chemistry of monoamine oxidase has more than heuristic value. If we know what cofactors are necessary for the action of the enzyme we can try to block this action by using co-factor analogues. If we know the types of linkage on the protein 
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Rat liver and Tyramine, iso-amylamine, (A flavin co-enzyme brain serotonin and other and a metal co-factor monoamines have been suggested) portion of the molecule which are intimately involved in the oxidation of amines, we may be able to design very specific and highly active inhibitors. If we learn that what we now call monoamine oxidase actually consists of two or more enzymes, each active in its own way, we can hope to be more specific about our correlations of inhibitory and antidepressive potency. Lest there be any doubts about this matter, one may remember that the use of enzyme measurements in clinical diagnosis (e.g. transaminase acid and alkaline phosphatase, lactic dehydrogenase, etc.) and in forensic medicine (e.g. alcohol dehydrogenase for the determination of alcohol concentration in the blood) has depended upon detailed knowledge of the physical chemistry of the enzymes.
Does the Aldehyde Product of MAO Action Have Any Biological Activity?
The aldehyde product resulting from the action of MAO on an amine is relatively labile in metabolism. It can be isolated by trapping it as it is formed, using a 'carbonyl reagent', after which it may be regenerated by suitable chemical means. Otherwise, it undergoes conversion very quickly: by reduction to form an alcohol, as is now well known for the catecholamines and tryptamine; or by further oxidation to form a carboxylic acid such as VMA (vanillylmandelic acid) in the case of noradrenaline and adrenaline, homovanillic acid from dopamine, 5-hydroxyindoleacetic acid from serotonin, and so on. Renson et al. (22) studied the action of the aldehydes formed from noradrenaline, serotonin, tryptamine and histamine on smooth muscle preparations and found no pharmacological activity whatsoever. We must still inquire about the activity of these aldehydes in the brain. Barondes (1) has observed a metabolic effect of monoamines on the utilization of glucose-I-X; by beef anterior pituitary slices. This effect is shown only by amines that are substrates for MAO; it is blocked by inhibitors of MAO but then certain aldehydes can be used to get around this block. Hence, there is the possibility that aldehydes possess this particular metabolic action.
Holtz and his colleagues have found another type of action of the aldehyde derived from dopamine (13): 3,4-dihydroxyphenylacetaldehyde reacts molecule for molecule with dopamine itself to form tetrahydropapaveroline, an alkaloid with vasodepressor, cardiostimulatory and smooth muscle-inhibitory actions that are sensitive to the~-receptor blocking agent nethalide.
Thus, the aldehydes derived from the alkaromatic amines require further study in respect to metabolic and pharmacological actions on the central nervous system. If these substances are formed at neuronal endings or at synapses, then what actions, if any, do they have there? And if they do have some action, what happens to that activity when the administration of an MAO inhibitor reduces the rate of their formation?
The Relation of MAO Inhibition to the Other Actions of MAO Inhibitors
In much of the discussion about MAO inhibitors a uniformity of their action is implied. This is unfortunate, for the various MAO inhibitors are not qualitatively similar in all their actions, and the assumption that they are, or may be, clouds an important issue in biochemical pharmacology. Qualitative differences have been found in respect to amine changes in the urine (6) and brain (5), the concentration of high-energy phosphates of the brain (17), pharmacological effects (6, 18, 21) , toxic effects (18) , and antitoxic actions (32) . These 'different' effects are not to be considered as anomalies, or exceptions to any preconceived rule; some of the effects are worthy of further investigation.
Virtually all the MAO inhibitors are classed as 'irreversible', that is, on dilution of the inhibited enzyme preparation no dissociation occurs, nor is the inhibitor readily displaced by an excess of substrate. Methylene blue and harmine are reversible inhibitors which, when administered to the animal, will prevent the action of a hydrazide inhibitor (9, 14, 15) , but not that of tranylcypromine (14, 15) . The inhibition of the enzyme with methylene blue may be complete, yet the brain amines do not rise. Dubnick et al. (8) , on the other hand, have found that with apparently complete inhibition of mouse brain MAO using aralkylhydrazine irreversible inhibitors, the serotonin concentration in that organ can be made to increase with additional doses of the inhibitor. One possibility that they suggest is that very small amounts of MAO activity, within the error of present measurements, still plays a physiological role, and that this activity can be abolished only by extremely high doses of the inhibitor in order to achieve the furthest extension of the slowly-rising upper limb of a sigmoid dose-response curve.
Now that the main effects of the MAO inhibitors have been studied in such great detail, it would be worth assessing the . specific pharmacology of the more important ones in relation to amine and metabolic changes, and to determine which of the biological actions stem from inhibition of MAO, and which do not.
The Relation of Acute to Chronic Effects of MAO Inhibitors
Almost all the work on brain and other amines using MAO inhibitors has been carried out in acute experiments. The results are then applied to the interpretation of the drug effects observed in depressed patients receiving the drug chronically. It is felt that some animal work ought to be carried out using smaller doses administered over a long period of time, in order to mimic clinical use of these drugs. The long wait for results should be profitable.
The Problem of the Function of Brain Amiues
Acetylcholine is the only amine whose function as a transmitter in the brain has been attested to by the physiologists, pharmacologists and biochemists. The function of y-aminobutyric acid is not yet understood. Noradrenaline is a neurotransmitter in the autonomic nervous system, and is thought to be one in the brain. In spite of much basic work on serotonin, its function is still unknown. Both noradrenaline and serotonin occur in relatively high concentrations in certain parts of the brain, and not in others, and this uneven distribution is undoubtedly related to special roles in the pertinent regions for these two compounds. Tryptamine and histamine are also found in the brain, but even less is known about them.
For some years it has been known that DOPA can temporarily overcome the depressant actions of reserpine (4, 7, 3, 10), although 5-hydroxytryptophan, the precursor of serotonin, does not do so (4) . The DOPA gives rise to large amounts of cerebral dopamine (19) . Although some of this presumably is converted to noradrenaline, which may have independent actions, there is considerable evidence that dopamine itself is an imp orportant 'action substance' in the brain (reviewed in reference 26). Dopamine is found in high concentrations in the basal ganglia of the brain (2, 23, 16) , and lately we have been investigating the relationship of certain of these ganglia to one another, as reflected in their amine content. Our method has consisted of placing unilateral electrolytic lesions in the ventromedial tegmental area of the brain stem of rhesus monkeys. After a long period of time (1-9 months) the animals are killed; the striatum is taken for analysis of its amine content, and the brain-stem is kept for microscopic study. In our first series of animals (20) the lesions in six resulted in, a) loss of cells of the paYs compacta of the ipsilateral Substantia nigra and, b) a low concentration of dopamine and noradrenaline in the corresponding striatum (18-42% of the values found on the unoperated side). In 12 monkeys the tegmental lesion did not affect the cellularity of the Substantia nigra, nor did it alter the concentration of dopamine and noradrenaline in the corresponding striatum significantly. In another series of seven monkeys prepared similarly, the four with cell loss in the Substantia nigra had 81-100% loss of striatal dopamine; serotonin was not significantlv affected (27) . None of these anim;ls showed any important clinical signs. However, more recently, we have obtained several monkeys with obvious tremor of the contralateral limbs, and in these the striatal serotonin is low. Our results suggest that the pars compacta of the Substantia nigra normally exerts through its efferent pathways a direct influence on the concentration of catecholamines of the corresponding striatum. As for the 'serotonin-low' animals, we hope that the forthcoming histological examination of the brains will reveal an associated specifically located lesion.
We have not had sufficient time to carry out extensive drug trials in these brain-lesioned monkeys, but quite clearly where brain amines are involved the antidepressant MAO inhibitors ought to provide some additional critical conditions for our experiments. One cannot suggest at the present time that the role of serotonin or of dopamine in all parts of the brain can be elucidated by this technique, but it certainly represents a novel method for tracing neural pathways in the central nervous system, and is relevant to the assessment of the function of brain ammes.
Conclusion
This paper has dealt with some problems in regard to antidepressant medication, illustrated by data drawn from the basic medical sciences. The review and evaluation of MAO inhibitors used in therapy that took place in 1964 (d. reference 28) was a necessary procedure that might not even have been necessary if there had been controlled clinical studies of these various drugs made from the start of their use. It is doubted whether there has been any retrenchment in their use in psychiatry resulting from the general recognition of their toxicity, but has the great interest of the pharmaceutical industry in synthesizing new MAO inhibitors in the vears from 1957 to 1964 not now abated or even terminated? If it has, then we can expect a recession in research on MAO and its inhibitors. For the problems considered important by the drug industry inevitably exert a stimulatory influence upon pharmacological research in academic centres, and problems that the former set aside lose some of that glow which had earlier mobilized the intellectual resources of the research community. The consequences would be regrettable, because the problems of the mechanism of depression and the treatment of depression, to which the basic medical sciences can yet contribute so much, will remain unsolved too long.
Resume
La communication ici presentee fait etat des problernes souleves par la medication antidepressive en illustrant les donnees tirees des sciences medicales de base. La revision et I'evaluation des inhibiteurs MAO employes dans la therapie qu'on fit en 1964 (d. reference 28) fur une tache necessaire dont on aurait pu se dispenser si des etudes cliniques controlees de ces divers medicaments avaient ete effectuees des qu'on commenc;a aen faire usage. L'auteur a des doutes asavoir s'il s'est produit une certaine restriction dans leur emploi en psychiatrie, dli a I'admission generale de leur toxicite, et se demande si Ie grand interet apporte par l'industrie pharmaceutique aproduire de nouveaux inhibiteurs synthetiques de la MAO entre 1957 et 1964 n'est pas maintenant fort diminue, pour ne pas dire eteint, Si tel etait Ie cas, I'auteur est d'avis qu'il faudrait s'attendre a une marche arriere en ce qui concerne la recherche sur la MAO et ses inhibiteurs. II se trouve que les problemes juges d'importance par l'industrie pharmaceutique exercent une influence stimulante sur la recherche pharmacologique dans les centres academiques. Lorsque I'industrie se desinteresse de certains problernes, ceux-ci perdent l'eclat de la nouveaute qui avait alors mobilise les ressources intelIectuelIes des equipes de chercheurs. Ceci peut avoir des consequences deplorables, car les problemes que suscitent les mecanismes de la depression et son traitement, et auxquels les sciences medicales de base peuvent accorder encore une si grande contribution, risquent de demeurer trop longtemps sans solution.
